anti-melanoma mab fragments
Various (V09)Various (V09) compound in Xijing Hospital's portfolio. Mechanism: Diagnostic agent.
- Mechanism
- Diagnostic agent
pharma · Melanoma · Multiple Myeloma
Xijing Hospital
Xijing Hospital drug portfolio — 5 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
CN HQ
NMPA registrant Type
Company details
- Status
- Public
- HQ
- CN
- Programs
- 4
- Drugs
- 5
- Patents
- 0
Xijing Hospital pipeline
Portfolio lens on 5 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Xijing Hospital drug portfolio — 5 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
Development asset linked to Xijing Hospital in public FDA and regional records.
-
Development asset linked to Xijing Hospital in public FDA and regional records.
-
folic acid
Various (V04)US regulatory status: approved.
-
Development asset linked to Xijing Hospital in public FDA and regional records.